Wikipedia

Pimodivir

Pimodivir (VX-787, JNJ-63623872) is an antiviral drug which was developed as a treatment for influenza. It acts as an inhibitor of influenza virus polymerase basic protein 2, and has shown promising results in Phase II clinical trials.[1][2][3] However, in late 2021, Janssen announced that the clinical development of pimidivir had been halted due to lack of benefit over standard of care.[4]

Pimodivir
Clinical data
Trade namesPimodivir
Legal status
Legal status
Identifiers
  • (2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC20H19F2N5O2
Molar mass399.402 g·mol−1
3D model (JSmol)
  • O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F
  • InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1
  • Key:JGPXDNKSIXAZEQ-SBBZOCNPSA-N

See also

edit

References

edit
  1. ^ Trevejo JM, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y, et al. (2018). "Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study". Antiviral Therapy. 23 (4): 335–344. doi:10.3851/IMP3212. PMID 29244026. S2CID 4005581.335-344&rft.date=2018&rft_id=https://api.semanticscholar.org/CorpusID:4005581#id-name=S2CID&rft_id=info:pmid/29244026&rft_id=info:doi/10.3851/IMP3212&rft.aulast=Trevejo&rft.aufirst=JM&rft.au=Asmal, M&rft.au=Vingerhoets, J&rft.au=Polo, R&rft.au=Robertson, S&rft.au=Jiang, Y&rft.au=Kieffer, TL&rft.au=Leopold, L&rfr_id=info:sid/en.wikipedia.org:Pimodivir" class="Z3988">
  2. ^ Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, et al. (March 2019). "Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial". The Journal of Infectious Diseases. 219 (7): 1026–1034. doi:10.1093/infdis/jiy547. PMID 30428049.1026-1034&rft.date=2019-03&rft_id=info:doi/10.1093/infdis/jiy547&rft_id=info:pmid/30428049&rft.aulast=Finberg&rft.aufirst=RW&rft.au=Lanno, R&rft.au=Anderson, D&rft.au=Fleischhackl, R&rft.au=van Duijnhoven, W&rft.au=Kauffman, RS&rft.au=Kosoglou, T&rft.au=Vingerhoets, J&rft.au=Leopold, L&rft_id=https://doi.org/10.1093%2Finfdis%2Fjiy547&rfr_id=info:sid/en.wikipedia.org:Pimodivir" class="Z3988">
  3. ^ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (July 2019). "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research. 167: 45–67. doi:10.1016/j.antiviral.2019.04.006. PMC 7132446. PMID 30974127.45-67&rft.date=2019-07&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132446#id-name=PMC&rft_id=info:pmid/30974127&rft_id=info:doi/10.1016/j.antiviral.2019.04.006&rft.aulast=Beigel&rft.aufirst=JH&rft.au=Nam, HH&rft.au=Adams, PL&rft.au=Krafft, A&rft.au=Ince, WL&rft.au=El-Kamary, SS&rft.au=Sims, AC&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132446&rfr_id=info:sid/en.wikipedia.org:Pimodivir" class="Z3988">
  4. ^ "Janssen's lead coronavirus vaccine shows preclinical promise". 4 September 2020.
 

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pimodivir&oldid=1215441312"